<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03034317</url>
  </required_header>
  <id_info>
    <org_study_id>20-1000-51</org_study_id>
    <nct_id>NCT03034317</nct_id>
  </id_info>
  <brief_title>NeuRx Diaphram Pacing System (DPS) Use in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>PARADIGM</acronym>
  <official_title>Multi-Center, Concurrent-Controlled, On-Label Study of the NeuRx Diaphragm Pacing System (DPS) in Participants With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synapse Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synapse Biomedical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to collect more information about the use, safety, and
      effectiveness of the NeuRx DPSÂ® in ALS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Characterize the safety and benefit of on-label Humanitarian Device Exemption (HDE) use of
      DPS in patients with ALS who initiated noninvasive ventilation (NIV).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Compare the survival of patients who initiated noninvasive ventilation (NIV).and who receive DPS to controls without DPS: (1) concurrent controls; (2) historical controls (e.g., Lechtzin and PRO-ACT databases); and (3) virtual controls (Origent).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between survival time and clinical features of ALS</measure>
    <time_frame>24 months</time_frame>
    <description>Determine whether there is a relationship between survival time and ALS onset type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between survival time and ALS assessment scores</measure>
    <time_frame>24 months</time_frame>
    <description>Determine whether there is a relationship between survival time and Upper Motor Neuron (UMN)/ Lower Motor Neuron (LMN) assessment scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between survival time and onset of weakness from ALS to treatment</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between survival time and ALS treatment interventions</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between survival time and intraoperative strength of contraction</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize change in overall and respiratory function</measure>
    <time_frame>24 months</time_frame>
    <description>Characterize longitudinal change in overall function (ALSFRS-R) before and after treatment with DPS compared to controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize change in respiratory function</measure>
    <time_frame>24 months</time_frame>
    <description>Characterize longitudinal change in respiratory function (FVC, MIP) before and after treatment with DPS compared to controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types device and procedure-related adverse events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of device and procedure-related adverse events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Types of respiratory serious adverse events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of respiratory adverse events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>NeuRx DPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who have initiated noninvasive ventilation (NIV) and receive the NeuRx diaphragm pacing system (DPS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No DPS</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects who have initiated noninvasive ventilation (NIV) and do not receive the DPS device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuRx DPS</intervention_name>
    <description>Patients who are diagnosed with ALS, have initiated NIV and choose to have the NeuRx DPS implanted.</description>
    <arm_group_label>NeuRx DPS</arm_group_label>
    <other_name>Diaphragm Pacing System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21 or older

          -  Familial or sporadic ALS diagnosed as possible, laboratory-supported probable,
             probable, or definite according to the World Federation of Neurology El Escorial
             criteria

          -  Bilateral phrenic nerve function clinically acceptable as demonstrated by bilateral
             diaphragm movement with fluoroscopic sniff test or with phrenic nerve conduction
             studies

          -  Chronic hypoventilation was documented by at least one of the following:

               -  MIP (respiratory muscle strength) less than 60 cmH2O, or

               -  Forced Vital Capacity (FVC) less than 50% predicted, or

               -  PaCO2 greater than or equal to 45 mmHg, or

               -  Nocturnal SaO2 (arterial oxygen saturation) less than or equal to 88% for at
                  least five continuous minutes

          -  Initiation of non-invasive ventilation at or before time of enrollment

          -  Suitable surgical candidate to receive diaphragm pacing stimulation

          -  Negative pregnancy test in female participants of childbearing potential (treatment
             group)

          -  Informed consent from patient or designated representative

        Exclusion Criteria:

          -  FVC less than 45% predicted within 10 days prior to surgery.

          -  Participation in simultaneous therapeutic clinical trial which could affect the safety
             or benefit outcomes of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Pacific Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeff Thompson</last_name>
    <phone>440-774-2488</phone>
    <phone_ext>121</phone_ext>
    <email>jthompson@synapsebiomedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Fritz</last_name>
    <phone>440-774-2488</phone>
    <phone_ext>134</phone_ext>
    <email>mfritz@synapsebiomedical.com</email>
  </overall_contact_backup>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diaphragm Pacing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

